Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CDH6/exatecan ADC CUSP06

An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6; K-cadherin) conjugated, via a protease cleavable linker, to the camptothecin analog and cytotoxic DNA topoisomerase I inhibitor exatecan, with potential antineoplastic activity. Upon administration of anti-CDH6/exatecan ADC CUSP06, the anti-CDH6 antibody moiety targets and binds to CDH6-expressing tumor cells. Upon uptake and cleavage of the linker by proteases, exatecan targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and induction of apoptosis. This inhibits the proliferation of CDH6-expressing tumor cells. In addition, this may cause a bystander effect, thereby further killing CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-cadherin-6 ADC CUSP06
anti-CDH6 ADC CUSP06
CDH6-targeting antibody-drug conjugate CUSP06
Code name:AMT 707
AMT-707
AMT707
CUSP 06
CUSP-06
CUSP06
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search